Neuphoria Therapeutics Inc. (NEUP) stock
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
$2.55−0.03 (-1.16%)
Close on Nov 13, 2026Market cap $76.66KP/E –Yield –
Neuphoria Therapeutics cash
Cash and short-term investments held at the end of each period.
Neuphoria Therapeutics's cash was $19.87M at Jun 30, 2026. For fiscal 2026 it was $19.87M, up 39.8% from the year before. The highest annual figure on record is $23.21M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $19.87M | +39.8% |
| FY2025 | Jun 30, 2025 | $14.21M | +12.0% |
| FY2024 | Jun 30, 2024 | $12.69M | +4.1% |
| FY2023 | Jun 30, 2023 | $12.18M | -47.5% |
| FY2022 | Jun 30, 2022 | $23.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $19.87M | +39.8% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $19.44M | +14.1% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $22.17M | +410.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $13.65M | +68.9% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $14.21M | +12.0% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $17.04M | +102.3% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $4.34M | -57.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $8.08M | -0.6% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $12.69M | +4.1% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $8.43M | -63.7% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $10.15M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $8.14M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $12.18M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $23.21M | – |
See a number that looks wrong?